Monte Rosa Therapeutics (NASDAQ:GLUE) Reaches New 1-Year Low - What's Next?

Monte Rosa Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Monte Rosa Therapeutics shares hit a new 52-week low, falling to $8.78 and recently trading at $8.85, down from the prior close of $9.07.
  • Despite the decline, analysts’ consensus remains Moderate Buy, with an average price target of $26.44; Wells Fargo lowered its target to $25 while keeping an Overweight rating.
  • The company beat quarterly expectations, reporting EPS of $0.03 versus estimates for a $0.21 loss, and revenue of $54.37 million against forecasts of $33.87 million.
  • Interested in Monte Rosa Therapeutics? Here are five stocks we like better.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) shares reached a new 52-week low during mid-day trading on Thursday. The company traded as low as $8.78 and last traded at $8.85, with a volume of 307,526 shares changing hands. The stock had previously closed at $9.07.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Wells Fargo & Company cut their price objective on Monte Rosa Therapeutics from $27.00 to $25.00 and set an "overweight" rating on the stock in a research report on Friday, November 6th. Zacks Research raised shares of Monte Rosa Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 4th. TD Cowen upgraded shares of Monte Rosa Therapeutics to a "strong-buy" rating in a report on Monday, August 24th. Guggenheim reiterated a "buy" rating and set a $28.00 price objective on shares of Monte Rosa Therapeutics in a report on Tuesday, August 25th. Finally, HC Wainwright initiated coverage on shares of Monte Rosa Therapeutics in a report on Thursday, October 1st. They set a "buy" rating and a $25.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $26.44.

View Our Latest Stock Report on Monte Rosa Therapeutics

Monte Rosa Therapeutics Stock Down 2.0%

The company has a market capitalization of $759.22 million, a price-to-earnings ratio of -6.36 and a beta of 1.40. The company's 50 day simple moving average is $11.00 and its two-hundred day simple moving average is $16.58.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.24. Monte Rosa Therapeutics had a negative net margin of 186.24% and a negative return on equity of 30.14%. The business had revenue of $54.37 million for the quarter, compared to analyst estimates of $33.87 million. Analysts anticipate that Monte Rosa Therapeutics, Inc. will post -0.94 EPS for the current year.

Institutional Trading of Monte Rosa Therapeutics

Institutional investors have recently bought and sold shares of the business. Algert Global LLC acquired a new position in Monte Rosa Therapeutics during the third quarter worth $1,985,000. Integral Health Asset Management LLC purchased a new stake in shares of Monte Rosa Therapeutics during the third quarter worth about $3,579,000. Entropy Technologies LP purchased a new stake in shares of Monte Rosa Therapeutics during the third quarter worth about $177,000. Jump Financial LLC raised its position in shares of Monte Rosa Therapeutics by 308.8% during the 3rd quarter. Jump Financial LLC now owns 142,681 shares of the company's stock worth $1,702,000 after purchasing an additional 107,781 shares during the last quarter. Finally, Empowered Funds LLC raised its position in shares of Monte Rosa Therapeutics by 17.5% during the 3rd quarter. Empowered Funds LLC now owns 387,020 shares of the company's stock worth $4,617,000 after purchasing an additional 57,754 shares during the last quarter. 79.96% of the stock is owned by institutional investors and hedge funds.

About Monte Rosa Therapeutics

(Get Free Report)

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders, medicines designed to direct disease-associated proteins for disposal by the cell. Its discovery platform combines computational and experimental methods to identify and develop these potential treatments. The company's research has included programs for cancer and immune-mediated diseases. Its pipeline includes MRT-6160, a VAV1 degrader being developed for autoimmune and inflammatory conditions, and MRT-8102, an investigational degrader targeting the NLRP3 inflammasome pathway.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Monte Rosa Therapeutics Right Now?

Before you consider Monte Rosa Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monte Rosa Therapeutics wasn't on the list.

While Monte Rosa Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines